TITLE

NICE gives go-ahead for rimonabant

PUB. DATE
July 2008
SOURCE
Pulse;7/9/2008, Vol. 68 Issue 24, p18
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the use of rimonabant in obese patients who cannot take orlistat and sibutramine by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. The institute has advised that there must be careful consideration of current or previous depressive disorders and regular monitoring in prescribing rimonabant. The recommendation of NICE also state that a patient must lose 5% of their body weight in order to continue the treatment.
ACCESSION #
33313163

 

Related Articles

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • Orlistat, sibutramine, and rimonabant reduce weight in overweight and obese persons. Kanaya, Alka M. // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p24 

    The article focuses on 30 randomized controlled trials (RCTs) investigating the long-term efficacy of antiobesity drugs (AODs) for reducing weight and improving health status in overweight or obese persons. Trials found out that orlistat, sibutramine and rimonabant reduces weight and improve...

  • Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients. Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C. // Journal of Obesity;2010, Vol. 2010, p1 

    Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were...

  • Success of dieting groups prompts call for QOF review. Robinson, Stephen // GP: General Practitioner;9/16/2011, p12 

    The article reports on Great Britain's National Institute for Health and Clinical Excellence (NICE), which will introduce more comprehensive obesity targets into the Quality and Outcomes Framework (QOF). A study which revealed that weight-loss clubs in Great Britain were effective at helping...

  • GPs urged to screen and manage patients' obesity. Robinson, Stephen // GP: General Practitioner;6/10/2011, p14 

    The article reports that the National Institute for Health and Clinical Excellence (NICE) has urged general practitioners (GPs) to offer weight management advice to the patients suffering from obesity in Great Britain. According to David Haslam, chairman the Quality Outcomes Framework (QOF)...

  • The Straight Dope On Weight-Loss Drugs. Fentress, Debbie; Agnew, Bruce // Diabetes Forecast;Apr2002, Vol. 55 Issue 4, p51 

    Provides information on weight-loss drugs, Xenical, Meridia and phentermine. Overview of studies on the drugs; Side effects of weight loss drugs; Contents of the drugs. INSET: Beware herbal remedies.

  • Antidote. Siegel, Marc // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p14 

    The article examines some weight loss drugs in the United States. Xenical or Orlistat are drugs that hinder fat absorption into the gastrointestinal tract. An appetite suppressant, Meridia prevents the reabsorption of serotonin, a hormone in the brain that is released when a patient is full from...

  • NICE GUIDANCE ON OBESITY. Cresswell, Jackie // HealthEX Specialist;May2007, Issue 12, p12 

    The National Institute for Health and Clinical Excellence (NICE) has just published guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children for England and Wales. This article sets out some of the recommendations and guidelines...

  • Suicide fears over weight-loss drug.  // PRWeek (London);7/4/2008, p6 

    The article looks at the suicide concerns over the weight-loss drug Acomplia, manufactured by Sanofi-Aventis. The drug has been approved by the British National Institute for Health and Clinical Excellence (NICE) and it is licensed in the Great Britain for the treatment of obese and overweight...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics